Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Investor Presentation
Q2 FY27
Investor Presentation
Q2 FY24
Bearish
4
Neutral
8
Bullish
2
Bearish
16
Neutral
12
Bullish
18
Bearish
12
Neutral
4
Bullish
16
Bearish
12
Neutral
4
Bullish
16
Bearish
12
Neutral
4
Bullish
16
Bearish
12
Neutral
4
Bullish
16
Discovery themes featuring this stock
Aatmaj Healthcare Limited operates multidisciplinary and super-specialty hospitals, clinics, diagnostics, and pharmacies under the JTP Hospitals brand across Gujarat and Madhya Pradesh, using a hub-and-spoke model focused on affordable tertiary care in tier-2 and tier-3 markets. Its core specialties include critical care, surgery, orthopedics, CTVS, obstetrics, gynecology, and emerging IVF services.
H1 FY27 revenue from operations rose 56.89% year-on-year to ₹16.96 crore, but EBITDA increased only 15.25% to ₹2.04 crore and PAT declined 27.45% to ₹0.37 crore. The divergence highlights that new-hub setup costs, clinician retainers, depreciation, and finance expenses are currently absorbing much of the revenue growth before anticipated operating leverage emerges.
The most notable balance-sheet improvement is working-capital recovery: trade receivables declined to ₹23.30 crore and debtor days fell from approximately 397 days in FY26 to 251 days in H1 FY27. Operating cash flow after tax improved to ₹0.42 crore, although receivables remain large relative to revenue and continued collection execution is essential.
Aatmaj Healthcare Limited is repositioning its network toward higher-margin specialty care, particularly IVF, fertility, complex surgery, and advanced orthopedics. The Vadodara IVF unit is operational, while the company intends to replicate fertility services across regional hubs, leveraging existing obstetrics, gynecology, NICU, and fetal-medicine referral channels.
The company combines expansion ambition with meaningful financial risk. Borrowings increased to ₹23.16 crore and H1 finance costs reached ₹98.74 lakh, while management is targeting approximately ₹40.55 crore of FY27 revenue; delivery therefore depends on improving occupancy, integrating acquired facilities, reducing expensive short-term debt, and converting institutional receivables into cash.
Healthcare Services
Hospital
51 Cr
Low Risk
89.4
60.9
6.4
1.0
25.50
16.70
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
59.75 | 82 Cr | 27.53 | 2.01 | 0.00 | 7.29 | 18.00 | 4.87 | ||
39.60 | 74 Cr | 185.55 | 2.16 | 0.00 | 12.05 | 13.76 | 0.35 | ||
42.05 | 57 Cr | 13.60 | 1.35 | 0.00 | 9.91 | 12.37 | 7.93 | ||
22.85 | 52 Cr | 90.60 | 1.02 | 0.00 | 1.11 | 3.46 | 0.72 | ||
40.25 | 46 Cr | 8.02 | 0.88 | 0.00 | 26.06 | 12.11 | 0.00 | ||
45.00 | 31 Cr | -383.00 | 2.39 | 0.00 | -0.59 | -2.79 | -0.54 | ||
69.35 | 30 Cr | -8.17 | 0.00 | 0.00 | 219.47 | -11.64 | -13.57 | ||
| Median: 7 Co. | — | 42.05 | 52 Cr | 13.60 | 1.35 | 0.00 | 9.91 | 12.11 | 0.35 |
Aatmaj Healthcare Ltd (AATMAJ) is currently trading at 22.55 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Aatmaj Healthcare Limited operates multidisciplinary and super-specialty hospitals, clinics, diagnostics, and pharmacies under the JTP Hospitals brand across Gujarat and Madhya Pradesh, using a hub-and-spoke model focused on affordable tertiary care in tier-2 and tier-3 markets. Its core specialties include critical care, surgery, orthopedics, CTVS, obstetrics, gynecology, and emerging IVF services. H1 FY27 revenue from operations rose 56.89% year-on-year to ₹16.96 crore, but EBITDA increased only 15.25% to ₹2.04 crore and PAT declined 27.45% to ₹0.37 crore. The divergence highlights that new-hub setup costs, clinician retainers, depreciation, and finance expenses are currently absorbing much of the revenue growth before anticipated operating leverage emerges. The most notable balance-sheet improvement is working-capital recovery: trade receivables declined to ₹23.30 crore and debtor days fell from approximately 397 days in FY26 to 251 days in H1 FY27. Operating cash flow after tax improved to ₹0.42 crore, although receivables remain large relative to revenue and continued collection execution is essential. Aatmaj Healthcare Limited is repositioning its network toward higher-margin specialty care, particularly IVF, fertility, complex surgery, and advanced orthopedics. The Vadodara IVF unit is operational, while the company intends to replicate fertility services across regional hubs, leveraging existing obstetrics, gynecology, NICU, and fetal-medicine referral channels. The company combines expansion ambition with meaningful financial risk. Borrowings increased to ₹23.16 crore and H1 finance costs reached ₹98.74 lakh, while management is targeting approximately ₹40.55 crore of FY27 revenue; delivery therefore depends on improving occupancy, integrating acquired facilities, reducing expensive short-term debt, and converting institutional receivables into cash.
Over the past 52 weeks, Aatmaj Healthcare Ltd has traded between a low of ₹16.70 and a high of ₹25.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Aatmaj Healthcare Ltd has a market capitalization of approximately 50.96. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Aatmaj Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 89.40 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 50.96 Cr, Aatmaj Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Aatmaj Healthcare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Aatmaj Healthcare Ltd is 89.40. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Aatmaj Healthcare management has indicated an implied FY27 revenue target of about ₹40.55 crore. The figure represents approximately 80% growth from FY26 revenue of ₹22.53 crore and is forward-looking guidance rather than a reported result.
Aatmaj Healthcare reported debtor days of about 251 in H1 FY27 versus about 507 in FY24, a reduction of 256 days. The company also reported about 397 debtor days in FY26, making the H1 FY27 figure 146 days lower than the prior full-year reading.
Revenue from operations was ₹16.96 crore in H1 FY27, up 54% from ₹10.81 crore in H1 FY26.
